 |
|
|
| |
Once-daily etravirine/raltegravir (400/800 mg) as maintenance regimen
|
| |
| |
CROI 2020
Reported by Jules Levin
Romain PALICH1, Yasmine DUDOIT1, Gilles PEYTAVIN2, Minh LE2, Cathia SOULIE3, Roland TUBIANA1, Clotilde ALLAVENA4, Laurence WEISS5, Ana MONTOYA FERRER6, Claudine DUVIVIER7,
Olivier BOUCHAUD8, Julie BOTTERO9, Aurore Durand10, Anne-Genevieve MARCELIN3, Lambert ASSOUMOU10, Christine KATLAMA1, for the ETRAL QD study group
1. Sorbonne University, Infectious Diseases department, Pitié-Salpêtriere hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France. 2. Paris 7 University, Toxicology and Pharmacology department, Bichat-Claude Bernard hospital, INSERM 1137, Paris, France. 3. Sorbonne University, Virology department, Pitié-Salpêtriere hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France. 4. Infectious Diseases department, University hospital, Nantes, France. 5. Paris Descartes University, Clinical Immunology department, Georges Pompidou hospital, AP-HP, INSERM 976, Paris, France. 6. Infectious Diseases department, University hospital, Montpellier, France. 7. University of Paris, Infectious Diseases department, Necker hospital, AP-HP, INSERM 1016, Paris, France. 8. Infectious Diseases department, Avicenne hospital, AP-HP, Paris, France. 9. Infectious Diseases department, Jean Verdier hospital, Paris, France. 10. Sorbonne University, Pierre Louis Epidemiology and Public Health institute (iPLESP), INSERM 1136, Paris, France
|
| |
|
|
|
|
|
